TY  - JOUR
T1  - Comparative effectiveness of anti–growth factor therapies for diabetic macular edema: Summary of primary findings and conclusions
AU  - O’Malley PG
Y1  - 2012/07/09
N1  - 10.1001/archinternmed.2012.2335
JO  - Archives of Internal Medicine
SP  - 1014
EP  - 1015
VL  - 172
IS  - 13
N2  - 
Diabetic macular edema (DME) is a common consequence of diabetic retinopathy and a leading cause of significantly impaired vision among patients with diabetes. For many years, the standard of care has been to treat DME with laser photocoagulation treatments to the macula. Recently, evidence has begun to accumulate demonstrating the effectiveness of injectable intravitreal drugs that inhibit vascular endothelial growth factor (VEGF). Although none of these agents has yet received Food and Drug Administration approval for this indication, off-label use is substantial. The objective of this review was to assess the clinical effectiveness and potential harms of all available anti-VEGF drugs: pegaptanib (Macugen), bevacizumab (Avastin), ranibizumab (Lucentis), and aflibercept (Eylea).

SN  - 0003-9926
M3  - doi: 10.1001/archinternmed.2012.2335
UR  - http://dx.doi.org/10.1001/archinternmed.2012.2335
ER  -